Journal
SCIENCE
Volume 334, Issue 6062, Pages 1573-1577Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.1208347
Keywords
-
Categories
Funding
- Ligue Nationale contre le Cancer (Equipes labelisees)
- Agence Nationale pour la Recherche (ANR)
- European Commission
- Fondation pour la Recherche Medicale (FRM)
- Fondation Bettencourt-Schueller Institut National du Cancer (INCa)
- Canceropole Ile-de-France
- LabEx OncoImmunology
- Association pour la Recherche sur le Cancer
- Italian Association for Cancer Research (AIRC)
- La Ligue Nationale contre le Cancer
- China Scholarship Council
- Higher Education Commission of Pakistan
- Fondation de France
Ask authors/readers for more resources
Antineoplastic chemotherapies are particularly efficient when they elicit immunogenic cell death, thus provoking an anticancer immune response. Here we demonstrate that autophagy, which is often disabled in cancer, is dispensable for chemotherapy-induced cell death but required for its immunogenicity. In response to chemotherapy, autophagy-competent, but not autophagy-deficient, cancers attracted dendritic cells and T lymphocytes into the tumor bed. Suppression of autophagy inhibited the release of adenosine triphosphate (ATP) from dying tumor cells. Conversely, inhibition of extracellular ATP-degrading enzymes increased pericellular ATP in autophagy-deficient tumors, reestablished the recruitment of immune cells, and restored chemotherapeutic responses but only in immunocompetent hosts. Thus, autophagy is essential for the immunogenic release of ATP from dying cells, and increased extracellular ATP concentrations improve the efficacy of antineoplastic chemotherapies when autophagy is disabled.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available